Neuropsychopharmacology Reports最新文献

{"title":"Effects of 3,4-methylenedioxymethamphetamine on neural activity in the nucleus accumbens of male mice engaged in social behavior.","authors":"Naoya Nishitani, Yuki Sasaki, Katsuyuki Kaneda","doi":"10.1002/npr2.12510","DOIUrl":"10.1002/npr2.12510","url":null,"abstract":"<p><p>3,4-methylenedioxymethamphetamine (MDMA), a commonly abused recreational drug, induces prosocial effects such as increased sociability and empathy. The nucleus accumbens (NAc) has been suggested to play a crucial role in these MDMA-mediated prosocial effects. However, the relationship between social behavior and NAc neural activity, and the effects of MDMA on this relationship, remain unknown. In this study, we measured NAc neural activity using fiber photometry and classified the behaviors of mice at times of transient increases in NAc neural activity during the social approach test (SAT). We found that NAc neural activity transiently increased at the onset of turning toward and sniffing novel mice during the SAT, although the frequency of turning was relatively low. We then examined the effects of MDMA on behavior and NAc neural activity and found that MDMA decreased the duration of sniffing per bout but did not alter NAc neural activity at the onset of turning toward or sniffing novel mice. These results suggest that MDMA does not affect the transient increase in NAc neural activity at the onset of social behaviors.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12510"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms.","authors":"Andrew Krystal, Pierre Blier, Larry Culpepper, Andrew A Nierenberg, Yoshikazu Takaesu, Naoki Kubota, Margaret Moline, Manoj Malhotra, Kate Pinner, Jane Yardley","doi":"10.1002/npr2.12509","DOIUrl":"10.1002/npr2.12509","url":null,"abstract":"<p><strong>Aim: </strong>Individuals with insomnia frequently have comorbid depression or anxiety. This study sought to provide a preliminary indication of the effects of lemborexant (LEM) in subjects treated for mild depression/anxiety symptoms.</p><p><strong>Methods: </strong>E2006-G000-303 (NCT02952820; EudraCT 2015-001463-39; SUNRISE-2) was a 12-month, phase 3, randomized, placebo-controlled, double-blind study where subjects with insomnia disorder were randomized (1:1:1) to placebo, LEM 5 mg (LEM5), or LEM 10 mg (LEM10) for 6 months. During the second 6 months (not reported), placebo-treated subjects were re-randomized to LEM5 or LEM10. In this post hoc analysis, changes from baseline (CFB) in subject-reported (subjective) sleep onset latency (sSOL), sleep efficiency (sSE), wake after sleep onset (sWASO), total sleep time (sTST), Fatigue Severity Scale, and Insomnia Severity Index were evaluated in subjects treated with medications for symptoms of depression/anxiety (subpopulation).</p><p><strong>Results: </strong>Of 949 randomized subjects, 61 treated with medications for symptoms of depression/anxiety were included. In the subpopulation, CFB comparing LEM with placebo were generally smaller than the overall population due to a larger placebo response in the subpopulation. However, the magnitudes of CFB within the active treatment groups for sSOL, sWASO, sTST, and sSE were similar between the subpopulation and the overall population. No new safety signals were observed in the subpopulation.</p><p><strong>Conclusion: </strong>LEM treatment benefited subjects with insomnia treated with medications for depression/anxiety symptoms, with no new safety signals. A greater placebo response in the subpopulation than in the overall population decreased the drug versus placebo effect size for LEM, as has been reported for other insomnia medications.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12509"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline for pharmacological treatment of schizophrenia 2022.","authors":"","doi":"10.1002/npr2.12497","DOIUrl":"10.1002/npr2.12497","url":null,"abstract":"","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12497"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Autism Spectrum Disorders and Dietary Intake of Carbohydrates in School-Aged Children in Iran: A Case-Control Study.","authors":"Shirin Tajadod, Zahra Roumi, Saheb Abbas Torki, Seyedeh Hayedeh Mousavi Shalmani, Mahdi Moradi, Zahra Saeedirad, Khadijeh Abbasi Mobarakeh, Saeideh Mohammadi, Soheila Shekari, Pouya Mirzaee, Parsa Bahmani, Anahita Houshyar-Rad, Saeid Doaei","doi":"10.1002/npr2.12521","DOIUrl":"10.1002/npr2.12521","url":null,"abstract":"<p><strong>Background: </strong>Autism spectrum disorder (ASD) is a neurodevelopmental disorder with both genetic and environmental risk factors. Imbalanced dietary Intake has recently been proposed as a possible environmental risk factor for ASD. The purpose of this study was to investigate the possible connection between ASD and intake of various carbohydrate types.</p><p><strong>Methods: </strong>110 patients with autism from 5 to 15 years of age have been included as the case group and 110 neurotypical children who are part of a similar age category have been chosen as controls for this case-control study. To estimate the dietary intake of carbohydrates, a validated food frequency questionnaire (FFQ) was used.</p><p><strong>Results: </strong>Positive connections were found between ASD and the intake of sugar (OR = 1.03, CI 95%: 1.02-1.06, p = 0.001), and maltose (OR = 2.09, CI 95%: 1.37-3.20, p = 0.001). A reverse correlation was found between ASD and dietary intake of carbohydrates (OR = 0.97, CI 95%: 0.96-0.98, p = 0.001), fructose (OR = 0.85, CI 95%: 0.77-0.94, p = 0.002), and lactose (OR = 0.89, CI 95%: 0.83-0.96, p = 0.002).</p><p><strong>Conclusion: </strong>This study showed a direct link between autism and the intake of sugar and maltose and an inverse connection between autism and the dietary intake of total carbohydrate, fructose, and lactose. There is a need to carry out additional long-term studies.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e12521"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Psychotropic Medications Taken by Pregnant Women on Newborn Medical Condition and Lactation Method.","authors":"Yuta Yoshino, Toru Yagi, Koichi Tsubouchi, Yusuke Takaishi, Yuki Ozaki, Jun-Ichi Iga, Keiichi Matsubara, Yuko Matsubara, Yuka Uchikura, Takashi Sugiyama, Shu-Ichi Ueno","doi":"10.1002/npr2.70005","DOIUrl":"10.1002/npr2.70005","url":null,"abstract":"<p><strong>Background: </strong>Maternal psychiatric condition during the perinatal period is relevant to children's cognitive development and mental health. Psychotropic medications are necessary to maintain the mental health of pregnant women with psychiatric disorders, but they are often avoided due to concerns about adverse effects, such as congenital malformations and abnormal neurodevelopment. A retrospective study of pregnant women with psychiatric disorders using psychotropic medications was performed to clarify maternal and child demographic data and to investigate whether psychotropic medications affected the Apgar score and the decision to breastfeed.</p><p><strong>Methods: </strong>Data of pregnant women with psychiatric disorders who were referred from the Department of Obstetrics and Gynecology to the Department of Neuropsychiatry at Ehime University Hospital from January 2014 to December 2022 were collected retrospectively. Pearson's chi-squared test and multiple regression analysis were used for statistical analyses.</p><p><strong>Results: </strong>A total of 226 women were included; 194 gave birth at our hospital, of whom 79 (40.7%) were taking psychotropic drugs at the time of delivery. None of the children had malformations. There was no relationship between the use of psychotropic medications and the choice to breastfeed. Multiple regression analysis showed that only the gestational weeks at birth were significantly associated with birth weight (p < 0.001) and Apgar score (1 min: p = 0.030; 5 min: p = 0.044).</p><p><strong>Conclusions: </strong>The use of psychotropic medications during the perinatal period appears safe and beneficial for both pregnant women with psychiatric disorders and their children, and breastfeeding should be considered even if the mother continues to take the medication. To clarify these points, prospective studies using large samples from several countries are needed.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e70005"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Clozapine Treatment for Treatment-Resistant Schizophrenia With Zinc Deficiency Severe Anemia: A Case Report.","authors":"Kaoru Matsuo-Yamamoto, Shinya Uenishi, Yuta Ishiyama, Shinichi Yamada, Yuji Kitabata, Kazuya Okamura, Sohei Kimoto","doi":"10.1002/npr2.12526","DOIUrl":"10.1002/npr2.12526","url":null,"abstract":"<p><strong>Introduction: </strong>Clozapine is an atypical antipsychotic drug approved for treatment-resistant schizophrenia (TRS). Despite its high efficacy for TRS, clozapine is associated with several serious adverse effects, such as neutropenia and diabetes, so it requires vigilant monitoring. Severe anemia has also been documented as a rare but serious complication with an unclear mechanism. We present a case report of severe anemia potentially associated with zinc deficiency during clozapine therapy.</p><p><strong>Case report: </strong>A 51-year-old woman was diagnosed with TRS without physical complications. Zinc deficiency was identified as a potential contributing factor. Zinc supplementation improved her hemoglobin levels, enabling the patient to continue clozapine at a therapeutic dose. The patient has remained stable, with no recurrence of anemia.</p><p><strong>Discussion: </strong>Clozapine is a highly effective antipsychotic, despite side effects including blood dyscrasias. While zinc deficiency is most likely to be implicated in clozapine-induced anemia, the exact mechanism remains unclear. Further research is required to explore this relationship between clozapine and zinc decrement.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e12526"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of psychiatric patients with nightmares after suvorexant administration: A retrospective study.","authors":"Kazuya Yasuda, Yoji Hirano, Ryuichiro Takeda, Ryuji Ikeda, Yasushi Ishida","doi":"10.1002/npr2.12506","DOIUrl":"10.1002/npr2.12506","url":null,"abstract":"<p><strong>Aim: </strong>Suvorexant is an orexin receptor antagonist (ORA) for the treatment of insomnia. The antagonistic action of suvorexant on orexin receptors is associated with an increase in rapid eye movement (REM) sleep, which can potentially lead to nightmares depending on the patient's condition. However, the precise risk factors for nightmares among patients taking ORAs, such as suvorexant, have yet to be identified. In this retrospective study, we aimed to identify the risk factors for the development of nightmares in patients treated with suvorexant.</p><p><strong>Methods: </strong>The risk factors were determined by comparing parameters between the nightmare group and the nonnightmare group. This study included 440 patients who received suvorexant at the University of Miyazaki Hospital from April 2014 to January 2021.</p><p><strong>Results: </strong>We found that 9.1% (n = 40) of the patients experienced suvorexant-induced nightmares. There was a significant difference in the median age, which was lower in the nightmare group than in the nonnightmare group (p < 0.01). Furthermore, both multiple logistic regression analysis and Cox proportional hazards regression analysis revealed increased odds ratios for nightmares for individuals aged 20-39 years.</p><p><strong>Conclusions: </strong>This study revealed that elderly patients taking suvorexant had fewer nightmares than nonelderly patients did.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"e12506"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Efficacies of a Blonanserin Transdermal Patch and Blonanserin Oral Formulation for Psychiatric Symptoms in Patients With Schizophrenia Treated With Laxatives Using a Japanese Claims Database.","authors":"Ken Inada, Hiroyuki Muraoka, Yuji Matsumoto, Daisuke Fukui, Tomomi Watanabe, Yuriko Masuda, Sachie Inoue, Takahiro Masuda","doi":"10.1002/npr2.70003","DOIUrl":"10.1002/npr2.70003","url":null,"abstract":"<p><strong>Background: </strong>Laxative use has recently been indicated as a risk factor for hospitalization in patients with schizophrenia. Oral antipsychotic therapy for patients with schizophrenia treated with laxatives may be problematic due to gastrointestinal dysfunction, which affects absorption. Therefore, transdermal patches of antipsychotics may be a suitable alternative. We herein compared the efficacies of a blonanserin (BNS) patch and BNS oral formulation in patients with schizophrenia treated with laxatives.</p><p><strong>Methods: </strong>A retrospective cohort study was performed using a claims database in Japan provided by DeSC Healthcare Inc. Subjects were BNS patch- or BNS oral formulation-prescribed patients with schizophrenia. The primary outcome was hospitalization to psychiatric wards. The hazard ratio (HR) for hospitalization was estimated using Cox proportional hazards model and adjusted by propensity scores.</p><p><strong>Results: </strong>Among the 3896 patients identified, 1407 were prescribed laxatives (BNS patch group: n = 538, BNS oral group: n = 869). Mean ages in the BNS patch and BNS oral groups were 74 and 58 years, respectively. The adjusted HR for hospitalization (BNS patch group vs. BNS oral group) was 1.31 (95% confidence interval; 0.88, 1.94), with no significant difference.</p><p><strong>Conclusions: </strong>No significant difference was observed in the risk of hospitalization for patients with schizophrenia treated with laxatives between the BNS patch and BNS oral groups. The effectiveness of antipsychotic patches in these patients warrants further research that considers factors such as patch preference in the elderly.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e70003"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Attentional Bias Modification Combined With Cognitive Behavioral Therapy in Reducing Relapse Risk and Cravings in Male Patients With Alcohol Use Disorder: A Quasi-Randomized Controlled Trial.","authors":"Yoshifumi Amano, Kohei Koizumi, Hirokazu Takizawa, Shota Tasaka, Toyohiro Hamaguchi","doi":"10.1002/npr2.70002","DOIUrl":"10.1002/npr2.70002","url":null,"abstract":"<p><strong>Background: </strong>Alcohol use disorder (AUD) is characterized by severe dependence on alcohol, poor impulse control, and heightened attention to alcohol-related cues. Attention bias modification (ABM) retrains individuals to distract attention from alcohol-related cues. This study investigates the effect of combining ABM with cognitive behavioral therapy (CBT) to reduce relapse risk and cravings in male patients with AUD.</p><p><strong>Methods: </strong>A quasi-randomized controlled trial was conducted among male inpatients diagnosed with AUD. Participants were divided into an intervention group receiving ABM in addition to CBT and a control group receiving CBT with a placebo intervention. The primary outcomes-risk of relapse and craving levels-were measured using the Alcohol Relapse Risk Scale (ARRS) and a visual analog scale (VAS), respectively. Participants underwent weekly sessions over 6 weeks, and outcomes were analyzed using generalized linear models (GLMs).</p><p><strong>Results: </strong>The analysis did not reveal significant interactions between the intervention group and time for ARRS scores and craving levels. Both groups experienced a reduction in relapse risk and cravings. However, there was no significant difference between the ABM + CBT and CBT-only groups.</p><p><strong>Conclusions: </strong>Although the combined ABM and CBT intervention did not result in statistically significant reductions in relapse risk and cravings compared to CBT alone, the overall reduction in these outcomes in both groups highlights the effectiveness of CBT in treating AUD. Future studies should use naturalistic settings and tailor the intervention to individual cognitive profiles.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e70002"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.","authors":"Minoru Urata, Hitoshi Sakurai, Fumihiko Ueno, Taku Maruki, Teruo Tada, Takahito Uchida, Yasuyuki Matsumoto, Masami Murao, Masayuki Tomita, Hajime Baba, Masaki Kato, Takashi Tsuboi, Koichiro Watanabe","doi":"10.1002/npr2.70008","DOIUrl":"10.1002/npr2.70008","url":null,"abstract":"<p><strong>Background: </strong>Mild depression lacks a consistent definition across diagnostic criteria and rating scales, posing challenges to standardizing treatment strategies. International guidelines predominantly recommend psychotherapy as the first-line treatment for mild depression, while the use of antidepressants remains contentious. Supplements such as omega-3 fatty acids, St. John's Wort, and magnesium have garnered attention as alternative therapeutic options for depression. This systematic review aims to assess the efficacy of pharmacological interventions, including supplements, in the treatment of mild depression.</p><p><strong>Methods: </strong>Comprehensive searches were performed in PubMed and Embase through November 2024 to identify randomized controlled trials (RCTs) investigating pharmacotherapy or supplements for mild depression diagnosed using standardized criteria. Eligible studies underwent screening and risk of bias assessment utilizing the ROB2 tool. Data on remission rates, symptom improvement, dropout rates, and adverse events were extracted, with meta-analyses conducted where applicable.</p><p><strong>Results: </strong>Eight RCTs comprising 1049 participants met inclusion criteria. Among the agents studied, St. John's Wort was analyzed in two trials, both comparing it to fluoxetine. A meta-analysis found no significant difference in response rates between the two treatments (risk ratio [RR] = 0.96, 95% CI: 0.78-1.18) or dropout rates (RR = 1.08, 95% CI: 0.62-1.88). For other agents, single studies evaluated their effects. Eicosapentaenoic acid and Rhodiola rosea demonstrated significant improvements in depressive symptoms compared to placebo. In non-blinded trials, magnesium chloride showed efficacy in alleviating depressive symptoms. Other interventions, such as lavender, lemon balm, and transcranial electroacupuncture stimulation, were as effective as antidepressants. Conversely, S-adenosylmethionine did not produce significant improvements relative to placebo.</p><p><strong>Conclusion: </strong>This review demonstrates that certain supplements, such as eicosapentaenoic acids and Rhodiola rosea, are therapeutic options for mild depression. However, no RCTs compared antidepressants directly to placebo for mild depression. The paucity of high-quality RCTs exclusively targeting mild depression limits definitive conclusions, warranting further rigorous research.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 1","pages":"e70008"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}